NCCN Updates Colorectal Cancer Guidelines to Include Braftovi and Mektovi

On March 18, Array BioPharma Inc. announced that the National Comprehensive Cancer Network has updated their Clinical Practice Guidelines to include Braftovi (encorafenib) in combination with Mektovi (binimetinib) and an anti-EGFR antibody as a Category 2a treatment for patients with BRAF-mutant metastatic colorectal cancer (mCRC) after failure of one or two prior lines of therapy for metastatic disease.

Read the Array press release here.

Posted 3/26/2019